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Abstract 
Innate immunity is increasingly recognised to contribute to the pathogenesis of 
neurodegenerative disorders. Here, Dejanovic et al. (2018) and Litvinchuk et al. (2018) 
describe mechanisms by which the complement system influences tau-mediated 
degeneration in mouse models of tauopathy.  
 
Main text 
Alzheimer’s disease (AD), the most common cause of dementia, affects more than 30 
million people worldwide and costs the world’s economies over $500 billion per year. An 
incomplete understanding of AD pathogenesis has thus far prevented the development of 
disease-modifying treatments. A potential pathway to synapse and neuron degeneration 
involves increased activation of the complement cascade, part of the brain’s innate immune 
system. Originally thought to be a secondary outcome to degenerative processes, a growing 
body of genetic and epidemiological evidence now strongly implicates cells and proteins 
involved in the innate immune system in modulating the risk of developing AD (De Strooper 
and Karran 2016, Henstridge et al. 2018). 
 
During normal brain development, microglia- and astrocyte-mediated synapse pruning is 
crucial in forming precise synaptic circuits (Stevens et al. 2007; Schafer et al. 2012). This 
process involves activation of the classical complement system, initiated by deposition of 
C1q on material to be eliminated. The cascade converges on the central complement 
component C3, whose fragments interact with their receptors, C3aR and CR3, to enact 
downstream immune effects such as phagocytosis.  
 
In disease, these developmental mechanisms might be reactivated, with glial engulfment of 
synapses contributing to synapse loss and disease progression. In AD patient brains, the 
pathological proteins amyloid-β (Aβ) and tau are thought to contribute to the synapse and 
neurons loss that causes dementia symptoms (Spires-Jones and Hyman 2014). There are 
several papers now linking Aβ-mediated synapse loss to the complement system in mouse 
models of AD. In plaque-bearing mouse models, C1q decorates post-synaptic densities that 
are then thought to be cleared by microglia through activation of CR3 (Hong et al. 2016). 
Although the complement pathway has been suggested to play an active role in tau 
pathology and tau-mediated synapse loss (Britschgi et al. 2012), the mechanisms remain 
unknown.  
 
In this issue of Neuron, Dejanovic et al. (2018) and Litvinchuk et al. (2018) provide 
mechanistic data linking tau pathology and the complement system. Both studies examined 
human brain tissue from AD and tauopathy patients as well as the PS19 mouse model of 
tauopathy, where animals express human tau containing the P301S frontotemporal 
dementia associated mutation. 
 
In the human AD brain, Dejanovic et al. found C1q and pathological tau proteins to be 
increased and enriched at post-synapses. Consistent with these proteins associating with 
one another, C1q levels positively correlated with the levels of pathological tau. Using 
RNAseq data from human AD patients, Litvinchuk et al. show that increased expression of 
the downstream complement components C3 and C3aR1 are associated with worsened 
cognitive function and with the degree of tau pathology. Additionally, in the brains of 
patients with other tauopathies which lack Aβ pathology, C3 and C3aR1 expression was also 
increased, supporting a role for complement components in human tauopathy. 
 
To probe how the complement system might influence tau-mediated synapse loss, 
Dejanovic et al. utilised the PS19 tauopathy mouse model at an age when they are in the 
early stages of disease progression, before they exhibit overt neuronal loss in their hands. 
Proteomics of post-synapses in these mice revealed C1q to be one of the most highly 
upregulated proteins. The amount of C1q present was positively correlated with the amount 
of pathological tau, like in the human AD brain. Temporally, the increase in synaptic C1q 
lagged slightly behind increases in pathological tau, consistent with tau inducing C1q 
accumulation at the synapse. Interestingly, C1q and human tau preferentially associated 
with one another at excitatory synapses, while inhibitory post-synapses were largely spared. 
C1q accumulation at post-synapses was also higher in the tauopathy mice than in a model of 
Aβ pathology, suggesting that pathological tau is particularly potent in activating the 
complement system. 
 
C1q-tagged synapses are thought to be engulfed by microglia, potentially contributing to 
synapse loss. In line with this, tau transgenic mice had reduced synapse density and 
microglia in these animals had increased levels of synaptic markers within lysosomes. Thus, 
pathological tau likely induces C1q accumulation at synapses, tagging them for removal by 
microglial phagocytosis. Notably, neutralisation of C1q in tau transgenic mice, via 
intracerebral injection of an anti-C1q antibody, reduced microglial engulfment of synaptic 
components and led to a small but significant rescue of synapse density 5 days after 
injection, highlighting the translational potential of these results.  
 
In addition to the C1q effects, proteomics in tau transgenic mice also revealed the 
downregulation of a group proteins that are involved in the regulation of Rho GTPases, 
which control actin dynamics and have previously been implicated as critical components in 
AD pathogenesis (Bolognin et al. 2014). Experimental depletion of these proteins in vitro 
resulted in reduced spine density that could be rescued by pharmacological stabilisation of 
actin. Thus, tau pathology may downregulate these proteins and lead to altered actin 
dynamics and subsequent spine loss, highlighting a molecular mechanism by which tau 
pathology may directly mediate synapse loss without the need for microglial engulfment.  
 
The paper by Litvinchuk et al. in this issue further supports a role for the complement 
system in the development of tau pathology, tau-mediated synapse degeneration and 
neuron loss. Following on from their finding that central complement components are 
increased in human tauopathies, Litvinchuk et al. examine how signalling by C3-C3aR 
modulates tau pathology by crossing PS19 mice with mice deficient in C3aR1, the gene for 
C3aR. Tau transgenic mice developed tau pathology, neuroinflammation, synapse and 
neuronal loss, and impairments of neuronal plasticity and cognition by 9 months of age in 
this study. Quite remarkably, upon knock out of C3aR1, somatodendritic accumulation of 
tau was almost completely ameliorated. This was accompanied by a curtailing of 
neuroinflammation, rescue of synapse and neuronal loss and improvements in neuronal 
function. Transcriptomics of bulk tissue and specific cell types (microglia and astrocytes) 
revealed a host of genes related to immune pathways to be upregulated in tau transgenic 
mice. Strikingly, deletion of C3aR1 normalised transcription of these immune-related genes 
and also reversed gene signatures typical of disease-associated microglia and neurotoxic 
astrocytes, which have been implicated in neurodegeneration, indicative of C3-C3aR 
signalling regulating these changes and mediating immune homeostasis in the context of 
tau pathology.  
 
Considering that deletion of C3aR1 had such widespread effects on many genes, Litvinchuk 
et al. postulated that C3aR may regulate transcription factors, particularly within microglia. 
Indeed, they identify the transcription factor STAT3 as a novel direct target and downstream 
effector of C3aR. Upon activation, the STAT family of transcription factors become 
phosphorylated and translocate to the nucleus where they mediate target gene 
transcription. Inhibition of STAT3 phosphorylation with a pharmacological compound was 
able to reduce tau pathology and neuroinflammation, although to a slightly lesser degree 
than C3aR1 knockout, providing novel insights into this pathway that may be amenable to 
therapeutic intervention.  
 
Both of these studies highlight a role for the complement system in modulating tau 
pathology and tau-mediated synapse loss. Taking these two studies together, it might be 
possible to hypothesise that, in regard to tau pathology, the complement system 
contributes to a ‘double-hit’ mechanism, perpetuating a cycle of exacerbated tau pathology 
and tau-mediated synapse loss (Fig.1). In such a cycle, enhanced activation of C3-C3aR 
signalling, potentially acting through STAT3, exacerbates tau pathology and 
neuroinflammation. Exacerbated tau pathology results in increased C1q tagging of synapses 
and subsequent synapse loss by microglial engulfment. Activation of the classical 
complement pathway via C1q leads to increased activation of C3 and increased signalling 
through C3aR, thereby perpetuating the cycle and exacerbating tau pathology and synapse 
loss, eventually leading to the gross neuronal loss and atrophy seen in AD.   
 
Although outstanding in many ways, the current studies do have limitations. These include 
using a single mutant tau overexpressing transgenic model for mechanistic studies. One 
example of a limitation of this model is apparent in the differing phenotypes observed at 
the same age between these two studies. Neuron loss was not observed by one group and 
was observed and modulated by knockout of C3aR1 by the other. Additionally, the human 
tau mutation in these transgenic models is associated with frontotemporal dementia and so 
may not be entirely representative of other tauopathies, such as AD. It will be valuable in 
future to repeat these studies in other tau mouse models including knock-in lines and to 
further test whether modulating the complement system can prevent or reverse synapse 
dysfunction, synapse loss and neuronal loss. Nonetheless, it is encouraging that in both 
papers, the authors include human tissue and/or data sets and report complementary 
findings to those in their mouse models, suggesting these data might be translationally 
relevant.  
 
Some key questions for future work remain. It is still not clear whether microglia 
phagocytose ‘live’ synapses or simply clear debris left by injured neurons. Although 
Dejanovic et al. suggest that, at least in vitro, microglia remove intact synapses, this requires 
further investigation. It will also be imperative to determine whether this occurs in human 
brain. It is interesting that Dejanovic et al. find inhibitory synapses to be largely protected 
from C1q-tagging and subsequent microglial engulfment. Imbalance of excitatory and 
inhibitory connections in the brain have repeatedly been implicated in many 
neurodegenerative diseases, and hopefully future work will determine why there appears to 
be preference for complement-mediated removal of excitatory synapses and how this 
impacts upon network function. It will also be important to identify synaptic receptors for 
C1q, which may help shed light on how synapses are selected for elimination, while also 
revealing targets more amenable to therapeutic intervention. In regard to Litvinchuk et al., 
an investigation into how C3-C3aR signalling influences the neuronal transcriptome might 
also reveal more mechanistic insight into how this pathway modulates tau pathology. 
 
In conclusion, both studies support a role of the complement system in tauopathy and tau-
mediated synapse degeneration, and highlight avenues for potential therapeutic 
intervention that warrant further investigation. This adds to a growing, dare we say 
“inflamed”, excitement in the field surrounding the cross-talk between multiple cell types in 
neurodegeneration. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Role of complement in the development of tau pathology and tau-mediated 
synapse loss. Litvinchuk et al. show C3-C3aR signalling is augmented in human tauopathies. 
C3aR can act directly through the transcription factor STAT3, which becomes 
phosphorylated (pSTAT3) and translocates to the nucleus to mediate immune-related gene 
expression, increasing neuroinflammation. This is likely heightened by cross-talk between 
microglia and astrocytes. Increased C3-C3aR signalling also exacerbates tau pathology in 
neurons. Exacerbated tau pathology likely increases synaptic tau levels, resulting in the 
tagging of synapses with C1q and subsequent microglial engulfment, as shown by Dejanovic 
et al., thus contributing to tau-mediated synapse loss. Microglia may also phagocytose tau-
containing synapses and contribute to the spread of tau pathology through the release of 
tau-containing exosomes that act as seeds. Activation of C1q leads to the initiation of the 
classical complement cascade, increasing C3-C3aR signalling and perpetuating the cycle of 
exacerbated tau pathology and synapse loss.  
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